Nano-particulate drug delivery systems for camptothecins

Cancer Therapy

Volumn 8, Issue ISSUE A, 2010, Pages 90-104

  Patankar, Nilesh ^a,b   Waterhouse, Dawn ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Block copolymers; Camptothecins; Drug Delivery; Graft copolymers; Irinotecan; Liposomes; Lurtotecan; Micelles; Topotecan

Indexed keywords

10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; BELOTECAN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CHIMMITECAN DERIVATIVE; CISPLATIN; CYTARABINE; DAUNORUBICIN; DEOXYCHOLATE SODIUM; DISTEAROYLPHOSPHATIDYLCHOLINE; DNA TOPOISOMERASE; DOXORUBICIN; EXATECAN; FIRTECAN; IRINOTECAN; LIPOSOME; LURTOTECAN; MACROGOL; NANOPARTICLE; PACLITAXEL; POLYMER; RUBITECAN; SILATECAN DERIVATIVE; SUCROSOFATE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLOSIS; BREAST CANCER; CANDIDIASIS; COLLOID; COLORECTAL CANCER; CRYPTOCOCCOSIS; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG UPTAKE; EPIDEMIC MENINGITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LOW DRUG DOSE; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MICELLE; MYCOSIS; NANOENCAPSULATION; NEOPLASM; NEUTROPENIA; NONHUMAN; OVARY CANCER; RECOMMENDED DRUG DOSE; SARCOMA; STRUCTURE ACTIVITY RELATION; SYSTEMIC DISEASE; THROMBOCYTOPENIA; VISCERAL LEISHMANIASIS;

EID: 84869381433     PISSN: 15439135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Baker JH, Lam J, Kyle AH, Sy J, Oliver T, Co SJ, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SS, Bally MB, and Yapp DT (2008) Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res. 14, 7260-7271
2. Batist G, Gelmon KA, Chi KN, Miller WH, Jr., Chia SK, Mayer LD, Swenson CE, Janoff AS, and Louie AC (2009) Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res. 15, 692-700
3. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, and Lee LW (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposomeencapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 19, 1444-1454
4. Blanco E, Kessinger CW, Sumer BD, and Gao J (2009) Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood). 234, 123-131
5. Boehlke L, and Winter JN (2006) Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drug. Expert Opin Biol Ther. 6, 409-415
6. Burke TG, and Gao X (1994) Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J Pharm Sci. 83, 967-969
7. Burke TG, Mishra AK, Wani MC, and Wall ME (1993) Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry. 32, 5352-5364
8. Burke TG, Munshi CB, Mi Z, and Jiang Y (1995) The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci. 84, 518-519
9. Burke TGea (1992) Liposomal stabilization of camptothecin's lactone ring. J Am Chem Soc. 114, 8318-8319
10. Cabral H, Nishiyama N, Okazaki S, Koyama H, and Kataoka K (2005) Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release. 101, 223-23
11. Calvert AH GR, Poole C, Dark G et al (2002) Randomized phase II trial of two intravenous schedules of the liposomal topoisimerase I inhibitor, NX211, in women with relapsed epithelial ovarian cancer (OVCA): an NCIC CTG study. Proc Am Soc Clin Oncol 208a
12. Cheung BC, Sun TH, Leenhouts JM, and Cullis PR (1998) Loading of doxorubicin into liposomes by forming Mn2+-drug complexes. Biochim Biophys Acta. 1414, 205-216
13. Colbern GT, Dykes DJ, Engbers C, Musterer R, Hiller A, Pegg E, Saville R, Weng S, Luzzio M, Uster P, Amantea M, and Working PK (1998) Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin Cancer Res. 4, 3077-3082
14. Cortesi R, Esposito E, Maietti A, Menegatti E, and Nastruzzi C (1997) Formulation study for the antitumor drug camptotehcin: liposomes, micellar solutions and a microemulsion. International Journal of Pharmaceutics. 159, 9
15. Cui J, Li C, Wang L, Wang C, Yang H, Li Y, Zhang L, Guo W, and Liang M (2009) Ni2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation. Int J Pharm. 368, 24-30
16. Dadashzadeh S, Vali AM, and Rezaie M (2008) The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Int J Pharm. 353, 251-259
17. Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, Coleman R, Jayson G, Le T, Ellard S, Trudeau M, Vasey P, Hamilton M, Cameron T, Barrett E, Walsh W, McIntosh L, and Eisenhauer EA (2005) Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J Clin Oncol. 23, 1859-1866
18. Desjardins JP, Abbott EA, Emerson DL, Tomkinson BE, Leray JD, Brown EN, Hamilton M, Dihel L, Ptaszynski M, Bendele RA, and Richardson FC (2001) Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice. Anticancer Drugs. 12, 235-245
19. Drummond DC, Meyer O, Hong K, Kirpotin DB, and Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 51, 691-743
20. Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, and Kirpotin DB (2010) Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 141, 13-21
21. Drummond DC, Noble CO, Guo Z, Hong K, Park JW, and Kirpotin DB (2006) Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 66, 3271-3277
22. Drummond DC, Noble CO, Hayes ME, Park JW, and Kirpotin DB (2008) Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci. 97, 4696-4740
23. Duan K, Zhang X, Tang X, Yu J, Liu S, Wang D, Li Y, and Huang J (2009) Fabrication of cationic nanomicelle from chitosan-graft-polycaprolactone as the carrier of 7-ethyl-10-hydroxy-camptothecin. Colloids Surf B Biointerfaces. 76, 475-482
24. Duffaud F, Borner M, Chollet P, Vermorken JB, Bloch J, Degardin M, Rolland F, Dittrich C, Baron B, Lacombe D, and Fumoleau P (2004) Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. Eur J Cancer. 40, 2748-2752
25. Emerson DL, Bendele R, Brown E, Chiang S, Desjardins JP, Dihel LC, Gill SC, Hamilton M, LeRay JD, Moon-McDermott L, Moynihan K, Richardson FC, Tomkinson B, Luzzio MJ, and Baccanari D (2000) Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a lowclearance liposomal formulation of lurtotecan. Clin Cancer Res. 6, 2903-2912
26. Gabizon A, Dagan A, Goren D, Barenholz Y, and Fuks Z (1982) Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res. 42, 4734-4739
27. Gabizon A, Shmeeda H, and Barenholz Y (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 42, 419-436
28. Gao JM, Ming J, He B, Gu ZW, and Zhang XD (2008) Controlled release of 9-nitro-20(S)-camptothecin from methoxy poly(elthylene glycol)-poly(D, L-lactide) micelles. Biomedical Materials. 3, 7
29. Gelmon K, Hirte H, Fisher B, Walsh W, Ptaszynski M, Hamilton M, Onetto N, and Eisenhauer E (2004) A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers. Invest New Drugs. 22, 263-275
30. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, and Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 19, 3312-3322
31. Gore M, ten Bokkel Huinink W, Carmichael J, Gordon A, Davidson N, Coleman R, Spaczynski M, Heron JF, Bolis G, Malmstrom H, Malfetano J, Scarabelli C, Vennin P, Ross G, and Fields SZ (2001) Clinical evidence for topotecanpaclitaxel non--cross-resistance in ovarian cancer. J Clin Oncol. 19, 1893-1900
32. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, and Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep. 54, 461-470
33. Hamaguchi T, Doi T, Eguchi-Nakajima T, Kato K, Yamada Y, Shimada Y, Fuse N, Ohtsu A, Matsumoto S, Takanashi M, and Matsumura Y (2010) Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res. 16, 5058-5066
34. Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, Muro K, Yamada Y, Okusaka T, Shirao K, Shimada Y, Nakahama H, and Matsumura Y (2007) A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer. 97, 170-176
35. Hattori Y, Shi L, Ding W, Koga K, Kawano K, Hakoshima M, and Maitani Y (2009) Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J Control Release. 136, 30-37
36. Hsiang YH, Hertzberg R, Hecht S, and Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 260, 14873-14878
37. Hsiang YH, Lihou MG, and Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49, 5077-5082
38. Hsiang YH, and Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48, 1722-1726
39. Huh KM, Lee SC, Cho YW, Lee J, Jeong JH, and Park K (2005) Hydrotropic polymer micelle system for delivery of paclitaxel. J Control Release. 101, 59-68
40. Jeong JH, Kim SH, Kim SW, and Park TG (2005) In vivo tumor targeting of ODN-PEG-folic acid/PEI polyelectrolyte complex micelles. J Biomater Sci Polym Ed. 16, 1409-1419
41. Johnston MJ, Edwards K, Karlsson G, and Cullis PR (2008) Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res. 18, 145-157
42. Kehrer DF, Bos AM, Verweij J, Groen HJ, Loos WJ, Sparreboom A, de Jonge MJ, Hamilton M, Cameron T, and de Vries EG (2002) Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J Clin Oncol. 20, 1222-1231
43. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, and Papahadjopoulos D (1997) Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry. 36, 66-75
44. Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, and Matsumura Y (2006) Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 66, 10048-10056
45. Krauze MT, Noble CO, Kawaguchi T, Drummond D, Kirpotin DB, Yamashita Y, Kullberg E, Forsayeth J, Park JW, and Bankiewicz KS (2007) Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol. 9, 393-403
46. Li CJ, Miyamoto Y, Kojima Y, and Maeda H (1993) Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br J Cancer. 67, 975-980
47. Li LH, Fraser TJ, Olin EJ, and Bhuyan BK (1972) Action of camptothecin on mammalian cells in culture. Cancer Res. 32, 2643-2650
48. Li Y, and Kwon GS (2000) Methotrexate esters of poly(ethylene oxide)-block-poly(2-hydroxyethyl-L-aspartamide). Part I: Effects of the level of methotrexate conjugation on the stability of micelles and on drug release. Pharm Res. 17, 607-611
49. Liu JJ, Hong RL, Cheng WF, Hong K, Chang FH, and Tseng YL (2002) Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation. Anticancer Drugs. 13, 709-717
50. Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 41, 189-207
51. Maeda H, Greish K, and Fang J (2006) The EPR effect and polymeric drugs: A paradigm shift for cancer chemotherapy in the 21st century. Advances in Polymer Science. 193, 103-121
52. Mahmud A, Xiong XB, Aliabadi HM, and Lavasanifar A (2007) Polymeric micelles for drug targeting. J Drug Target. 15, 553-584
53. McCarron PA, Marouf WM, Quinn DJ, Fay F, Burden RE, Olwill SA, and Scott CJ (2008) Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjug Chem. 19, 1561-1569
54. ME Wall MW, CE Cook, KH Palmer (1966) Plant antitumour agents, I: the isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc. 88, 3888-3890
55. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, Tardi P, Mayer LD, and Bally MB (2004) Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res. 10, 6638-6649
56. Mi Z, Malak H, and Burke TG (1995) Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry. 34, 13722-13728
57. Mizumura Y, Matsumura Y, Hamaguchi T, Nishiyama N, Kataoka K, Kawaguchi T, Hrushesky WJ, Moriyasu F, and Kakizoe T (2001) Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res. 92, 328-336
58. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, and Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep. 56, 515-521
59. Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, and Kataoka K (2003) Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res. 63, 8977-8983
60. Nishiyama N, Yokoyama M, Aoyagi T, TOkan T, Sakurai Y, and Kataoka K (1999) Preparation and characterization of selfassembled polymer-metal compolex micelle from cisdichlorodiammineplatinum(II) and poly(ethylene glycol)-poly(a, b-aspartic acid) block copolymer in an aqueous medium. Langmuir. 15, 7
61. Opanasopit P, Yokoyama M, Watanabe M, Kawano K, Maitani Y, and Okano T (2004) Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting. Pharm Res. 21, 2001-2008
62. Pal A, Khan S, Wang YF, Kamath N, Sarkar AK, Ahmad A, Sheikh S, Ali S, Carbonaro D, Zhang A, and Ahmad I (2005) Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res. 25, 331-341
63. Patankar N, Anantha M, Ramsay E, Waterhouse D, and Bally M (2011) The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C. Pharm Res. 28, 848-857
64. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 6, 789-802
65. Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, Edwards K, Karlsson G, Webb M, and Bally M (2006) Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res. 23, 2799-2808
66. Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, Webb M, Waterhouse D, and Bally M (2008a) A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and coppercontaining liposomes to improve drug retention. Eur J Pharm Biopharm. 68, 607-617
67. Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D, and Bally MB (2008b) Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clin Cancer Res. 14, 1208-1217
68. Ranjha NM (2009) Polymeric micelles of ammonium palmitoyl glycol chitosan and solubilization of camptothecin. PDA J Pharm Sci Technol. 63, 81-87
69. Saltz L (2000) Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer. Oncology (Williston Park). 14, 47-50
70. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, and Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 343, 905-914
71. Sawant RR, Sawant RM, and Torchilin VP (2008) Mixed PEGPE/ vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity. Eur J Pharm Biopharm. 70, 51-57
72. Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, Sivret J, Rusk J, and Barrett E (2004) A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol. 93, 229-232
73. Shao RG, Cao CX, Nieves-Neira W, Dimanche-Boitrel MT, Solary E, and Pommier Y (2001) Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene. 20, 1852-1859
74. Shi B, Fang C, You MX, Zhang Y, Fu S, and Pei Y (2005) Stealth MePEG-PCL micelles: effects of polymer composition on micelle physicochemical characteristics, in vitro drug release, in vivo pharmacokinetics in rats and biodistribution in S180 tumor bearing mice. Colloid Polymer Science. 283, 14
75. Simanek EE Cancer Therapies Utilizing the Camptothecins: A Review of in Vivo Literature. Mol Pharm
76. Srivastava V, Negi AS, Kumar JK, Gupta MM, and Khanuja SP (2005) Plant-based anticancer molecules: a chemical and biological profile of some important leads. Bioorg Med Chem. 13, 5892-5908
77. Sugarman SM, Zou Y, Wasan K, Poirot K, Kumi R, Reddy S, and Perez-Soler R (1996) Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies. Cancer Chemother Pharmacol. 37, 531-538
78. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, and Madden TD (2000) Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res. 60, 3389-3393
79. Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, and Mayer LD (2007) Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta. 1768, 678-687
80. Taylor RL, Williams DM, Craven PC, Graybill JR, Drutz DJ, and Magee WE (1982) Amphotericin B in liposomes: a novel therapy for histoplasmosis. Am Rev Respir Dis. 125, 610-611
81. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, and Kakizoe T (2005) Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer. 93, 678-687
82. Vali AM, Toliyat T, Shafaghi B, and Dadashzadeh S (2008) Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design. Drug Dev Ind Pharm. 34, 10-23
83. Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D, Bally MB, and Yapp DT (2011) Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C), doxorubicin (Caelyx(R) or vincristine. BMC Cancer. 11, 124
84. Wall ME, and Wani MC (1995) Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 55, 753-760
85. Wall ME, and Wani MC (1995) anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res. 50, 1693-1700
86. Wall ME, Wani MC, Nicholas AW, Manikumar G, Tele C, Moore L, Truesdale A, Leitner P, and Besterman JM (1993) Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J Med Chem. 36, 2689-2700
87. Wang J, Mongayt D, and Torchilin VP (2005) Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target. 13, 73-80
88. Wang M, Jiang M, Ning F, Chen D, Liu S, and Duan H (2002) Block-Copolymer-Free Strategy for Preparing Micelles and Hollow spheres: Self-Assembl of Poly(4-vinylpryidine) and Modified Polystyrene. Macromolecules. 35, 5980-5989
89. Wang Y, Ke C-Y, Beh CW, Liu S-Q, Goh S-H, and Yank Y-Y (2007) The self-assembly of biodegradable cationic polymer micells as vectors for gene transfection. Biomaterials. 28, 5358-5368
90. Watanabe M, Kawano K, Toma K, Hattori Y, and Maitani Y (2008) In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. J Control Release. 127, 231-238
91. Yokoyama M, Miyauchi M, Yamada N, Okano T, Sakurai Y, Kataoka K, and Inoue S (1990) Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)
92. Yokoyama M, Okano T, Sakurai Y, Fukushima S, Okamoto K, and Kataoka K (1999) Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. J Drug Target. 7, 171-186
93. Yokoyama M, Opanasopit P, Okano T, Kawano K, and Maitani Y (2004) Polymer design and incorporation methods for polymeric micelle carrier system containing water-insoluble anti-cancer agent camptothecin. J Drug Target. 12, 373-384
94. Yu NY, Conway C, Pena RL, and Chen JY (2007) STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models. Anticancer Res. 27, 2541-2545
95. Zamboni WC, Jung LL, Strychor S, Joseph E, Zamboni BA, Fetterman SA, Sidone BJ, Burke TG, Curran DP, and Eiseman JL (2008) Plasma and tissue disposition of nonliposomal DB-67 and liposomal DB-67 in C. B-17 SCID mice. Invest New Drugs. 26, 399-406
96. Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, Strychor S, Maruca L, Zamboni BA, Belani CP, and Ramanathan RK (2009) Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res. 15, 1466-1472
97. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, and Ahmad I (2004) Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm. 270, 93-107
98. Zhang X, Burt HM, Von Hoff D, Dexter D, Mangold G, Degen D, Oktaba AM, and Hunter WL (1997) An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemother Pharmacol. 40, 81-86
99. Zhang Y, Jin T, and Zhuo RX (2005) Methotrexate-loaded biodegradable polymeric micelles: preparation, physicochemical properties and in vitro drug release. Colloids Surf B Biointerfaces. 44, 104-109